Additionally, since most of the S100A12 activation is accompanied by IFI27 activation in patients with severe COVID-19, it is unlikely that the inability of ISG activation is to blame for most of the severe symptoms, which has implications in the usage of interferon as a therapeutic option. This evidence concerns the gene S100A12 and COVID-19.